The Difference Between Trastuzumab and Pertuzumab

Trastuzumab and Pertuzumab are two targeted drugs commonly used to treat HER2-positive breast cancer. They have some differences in their mechanisms of action and clinical applications. Trastuzumab and pertuzumab play different roles in the targeted treatment of HER2-positive breast cancer, and their combined use can provide a more comprehensive therapeutic effect.

Trastuzumab inhibits the growth and spread of HER2-positive breast cancer cells by bindingHER2 receptor and blocking its signaling pathway. Pertuzumab binds to different sites on the HER2 receptor and forms a complex with the HER2 receptor, inhibiting its interaction with the signaling molecules of other members, further inhibiting the growth of HER2-positive breast cancer cells. Trastuzumab is commonly used for the treatment of early and advanced HER2-positive breast cancer, and can be used alone or in combination with chemotherapy drugs, radiotherapy, etc. Pertuzumab is often used in combination with trastuzumab and chemotherapy drugs to treat early and advanced HER2-positive breast cancer. The results of clinical trials show that the combined use of trastuzumab and pertuzumab can significantly improve the therapeutic effect of patients with HER2-positive breast cancer and prolong disease progression-free time and survival.

Trastuzumab is sold under the brand name Herceptin in China and has entered the scope of Class B medical insurance, but it may be limited to patients who meet the indications for this drug, such as patients with HER2-positive metastatic breast cancer and its adjuvant and neoadjuvant treatment or HER2-positive metastatic gastric cancer. The price is around 6,000 yuan. The original trastuzumab drug has also been launched overseas. The drug ingredients of domestic and foreign original drugs are basically the same. For specific prices and drug details, you can consult the medical consultant. There is currently no generic drug of trastuzumab on the market.